タグリッソ錠の臨床経験調査（全症例調査）

基本情報

NCT ID

NCT02756039

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

3,494

治験依頼者名

AstraZeneca

概要

Clinical experience investigation (CEI) is to be conducted to confirm the following to characterise safety and efficacy of Tagrisso Tablets in actual clinical use. 1. Incidence of adverse drug reactions (ADRs) in actual clinical use 2. Factors which may affect safety and efficacy of the product (especially analysis of the incidence and risk factors of interstitial lung disease (ILD) events) 3. Information of ADRs not expected from "Precautions for Use" of the package insert in Japan

対象疾患

依頼者（Sponsor）